Findings

What do systematic reviews say?

101 questions · 108 findings · 9 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 7 · 6.5%GRADE not reported 0 · 0%Very low 17 · 15.7%Low 47 · 43.5%Moderate 37 · 34.3%High 0 · 0%

Budesonide MMX® 9 mg vs Entocort EC 9mg

Serious adverse events · Adult patients with active ulcerative colitis

Budesonide MMX® 9 mg showed no clear difference in serious adverse events compared with entocort EC 9mg (low certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 3.94 [0.45, 34.74]
1 study · 254 participants
Low

Budesonide MMX® 9 mg vs Entocort EC 9mg

Adverse events · Adult patients with active ulcerative colitis

Budesonide MMX® 9 mg showed no clear difference in adverse events compared with entocort EC 9mg (moderate certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 1.01 [0.81, 1.26]
1 study · 254 participants
Moderate

Budesonide MMX® 9 mg vs Entocort EC 9mg

Withdrawals due to adverse events · Adult patients with active ulcerative colitis

Budesonide MMX® 9 mg showed no clear difference in withdrawal due to adverse events compared with entocort EC 9mg (moderate certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 0.94 [0.56, 1.58]
1 study · 254 participants
Moderate

Budesonide MMX® 9 mg vs placebo

Histologic remission · Adult patients with active ulcerative colitis

Budesonide MMX® 9 mg may leads to higher histologic remission compared with placebo (low certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 1.51 [1.11, 2.06]
3 studies · 900 participants
Low

Budesonide MMX® 9 mg vs placebo

Endoscopic remission · Adult patients with active ulcerative colitis

Budesonide MMX® 9 mg probably leads to higher endoscopic remission compared with placebo (moderate certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 1.56 [1.13, 2.16]
2 studies · 695 participants
Moderate

Budesonide MMX® 9 mg vs placebo

Serious adverse events · Adult patients with active ulcerative colitis

Budesonide MMX® 9 mg showed no clear difference in serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 0.88 [0.33, 2.4]
2 studies · 513 participants
Low

Budesonide MMX® 9 mg vs placebo

Adverse events · Adult patients with active ulcerative colitis

Budesonide MMX® 9 mg showed no clear difference in adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 1.09 [0.95, 1.26]
3 studies · 971 participants
Moderate

Budesonide MMX® 6 mg vs placebo

Remission (combined clinical and endoscopic remission) · Adult patients with active ulcerative colitis

Budesonide MMX® 6 mg showed no clear difference in remission (combined clinical and endoscopic remission compared with placebo (low certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 1.8 [0.94, 3.42]
2 studies · 440 participants
Low

Budesonide MMX® 6 mg vs placebo

Clinical improvement · Adult patients with active ulcerative colitis

Budesonide MMX® 6 mg showed no clear difference in clinical improvement compared with placebo (low certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 0.99 [0.73, 1.33]
2 studies · 440 participants
Low

Oral viscous budesonide vs swallowed fluticasone

Clinical improvement (dichotomous) · active EoE patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral viscous budesonide vs swallowed fluticasone

Clinical improvement (continuous) · active EoE patients

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 84 participants
Low

Oral viscous budesonide vs swallowed fluticasone

Histological improvement (dichotomous) · active EoE patients

Oral viscous budesonide showed no clear difference in histological improvement at study endpoint (dichotomous) compared with swallowed fluticasone (low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 1.13 [0.84, 1.51]
1 study · 129 participants
Low

Oral viscous budesonide vs swallowed fluticasone

Histological improvement (continuous) · active EoE patients

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 111 participants
Low

Oral viscous budesonide vs swallowed fluticasone

Endoscopic improvement (dichotomous) · active EoE patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral viscous budesonide vs swallowed fluticasone

Endoscopic improvement (continuous) · active EoE patients

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 111 participants
Low

Oral viscous budesonide vs swallowed fluticasone

Withdrawals due to adverse events · active EoE patients

Oral viscous budesonide showed no clear difference in withdrawals due to adverse events at 8 weeks compared with swallowed fluticasone (low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 0.98 [0.42, 2.32]
1 study · 129 participants
Low

Budesonide/formoterol (BDF) vs placebo

Adverse events—'serious'—320/94 Duration of 10 months3 · COPD

Budesonide/formoterol (BDF) showed no clear difference in adverse events—'serious'—320/94 Duration of 10 months3 compared with placebo (low certainty).

1 finding from 1 review

Combined corticosteroid and long‐acting beta₂‐agonist in one inhaler versus placebo for chronic obstructive pulmonary… 2013 · Cochrane Headline outcomes only
OR 1.17 [0.95, 1.45]
2476 participants
Low

Budesonide/formoterol (BDF) vs placebo

Adverse events—'serious'—160/94 Duration of nine months 3 · COPD

Budesonide/formoterol (BDF) showed no clear difference in adverse events—'serious'—160/94 Duration of nine months 3 compared with placebo (low certainty).

1 finding from 1 review

Combined corticosteroid and long‐acting beta₂‐agonist in one inhaler versus placebo for chronic obstructive pulmonary… 2013 · Cochrane Headline outcomes only
OR 1.2 [0.89, 1.63]
1556 participants
Low

Budesonide/formoterol (BDF) vs placebo

Adverse event—any—320/94 Duration of nine months 3 · COPD

Budesonide/formoterol (BDF) may leads to higher adverse event—any—320/94 Duration of nine months 3 compared with placebo (low certainty).

1 finding from 1 review

Combined corticosteroid and long‐acting beta₂‐agonist in one inhaler versus placebo for chronic obstructive pulmonary… 2013 · Cochrane Headline outcomes only
OR 1.42 [1.16, 1.74]
1552 participants
Low

Budesonide/formoterol (BDF) vs placebo

Adverse event—any—160/94 Duration of nine months 3 · COPD

Budesonide/formoterol (BDF) may leads to higher adverse event—any—160/94 Duration of nine months 3 compared with placebo (low certainty).

1 finding from 1 review

Combined corticosteroid and long‐acting beta₂‐agonist in one inhaler versus placebo for chronic obstructive pulmonary… 2013 · Cochrane Headline outcomes only
OR 1.32 [1.08, 1.61]
1556 participants
Low